enantioselectivities were obtained, and triethyl phosphite
was added to reduce the peroxide intermediate. Optically
activecrown etherswerealsoshowntobeeffective asphase
transfer catalysts for R-hydroxylation of cyclic ketones
with molecular oxygen.6
the enantioselective Michael reactions of tert-butyl
glycinate-benzophenone Schiff base with high enantio-
selectivities and low catalyst loading.10 In this comm-
unication, we wish to report that R-hydroxylation of
3-substituted-2-oxindoles can be efficiently conducted
using pentanidium ascatalyst with high enantioselectivities.
Molecular oxygen was used as the oxidant, and contrary to
all previous reports, no reductant such as triethyl phosphite
was required (Figure 1, eq 2).
Figure 1. Enantioselective R-hydroxylation of 3-substituted-
2-oxindoles (1) with (EtO)3P as reductant (known),9b (2) without
reductant (this work).
Figure 2. Various chiral pentanidiums.
The oxidation of 3-methyl-2-oxindole 2a with air in the
presence of 5 mol % pentanidium 1a was initially con-
ducted with 2 equiv of triethyl phosphite as the reductant.
The solvent used was toluene with 50% aq KOH (v/v = 10:1)
and at a reaction temperature of À20 °C. The reac-
tion proceeded smoothly to afford 3-hydroxy-2-oxindole
3a with 52% yield and 56% ee in 12 h (Table 1, entry 1).11
We found that in the absence of triethyl phosphite, the
reaction also proceeded well. We were pleasantly surprised
when we found that the ee of 3a was increased to 67%.
However, significant amount of hydroperoxide oxindole
4a was detected as a side product (3a/4a = 70:30, entry 2).
Next, we tried to determine if the steric and electronic
properties of pentanidiums 1 (Figure 2) would alter the
product ratio and enantioselectivities. The use of more bulky
and electron-deficient benzylic groups on pentanidiums 1
improved the enantioselectivities (entries 3À5); pentanidium
1d afforded 3a with 92% ee (entry 5).11 Further optimization
of the reaction conditions were carried out by examining
different solvents with 1d as catalyst (entries 6À7); toluene
was identified as the ideal solvent.11 Lower reaction tem-
perature (À60 °C) improved the ee to 97% without loss of
reaction rate, but the ratio of 3a/4a was decreased to 43:57
(entry 9). We observed that the amount of molecular
oxygen affects the ratio of 3a/4a. When the amount of
air was restricted to 0.55 equiv of O2, the ratio of 3a/4a was
enhanced to 91:9, and ee of 3a was slightly decreased to
95% (entry 10). The hydroperoxide oxindole 4a could be
isolated and determined to have an ee of 36% ee (entry 10).
When a slightly lesser amount of O2 was used (0.4 equiv),
the ratio of 3a/4awasevenbetter, but the enantioselectivity
suffered slightly (82% ee, 3a/4a >95:5, entry 11). The ab-
solute configuration of 3a was designated as R by compar-
ing with an example in the literature, and the absolute
configuration of 4a was determined to be S via reduction.11
3-Substituted-3-hydroxy-2-oxindole is the core struc-
ture of a number of several natural products with a broad
spectrum of biological activities, and it is the focus of a
number of medicinal chemistry programs.7 The 3-hydroxy
position greatly affects the biological activities and
developing an efficient method to obtain enantiopure
3-hydroxy-2-oxindoles is critical for further investiga-
tions of these compounds.8 Shibata, Toru and co-workers
demonstrated the enantioselective R-oxidation of
3-substituted-2-oxindole using DBFOX-Zn(II) catalyst
and oxaziridine as oxidant.9a Subsequently, Itoh and co-
workers investigated the reaction under phase transfer con-
dition using molecular oxygen in the presence of Cinchona
alkaloid-derived catalyst (Figure 1, eq 1).9b Moderate to
good enantioselectivities were observed. More recently,
Barbas and co-workers utilized a dimeric quinidine to cat-
alyze the aminooxygenation of 3-substituted-2-oxindole with
nitrosobenzene as an approach toward chiral 3-hydroxy-
2-oxindoles.9c
Previously, we disclosed a new class of phase transfer
catalysts, pentanidiums, and showed that it can catalyze
(6) (a) Eckehard, V. D.; Volker, K. Liebigs Ann. Chem. 1992, 283–
285. (b) Vries, E. F. J.; Ploeg, L.; Colao, M.; Brussee, J.; Van der Gen, A.
Tetrahedron: Asymmetry 1995, 6, 1123–1132.
(7) (a) Satyamaheshwar, P. Curr. Bioact. Compd. 2009, 5, 20–38. (b)
Piyasena, H.; Nicholas, A. M. Bioorg. Med. Chem. Lett. 1997, 7, 1255–
1260. (c) Zhang, H.; Kamano, Y.; Yoshitatsu, I.; Haruhisa, K.; Kanki,
K.; Hideji, L.; George, R. P. Tetrahedron 1995, 51, 5523–5528.
(d) Teruhisa, T.; Hume, W. E.; Takashi, U.; Kazuhiko, O.; Yasuyuki,
U.; Kazuo, K.; Shinji, H.; Jun, N.; Hitoshi, S.; Mutsuo, T.; Hiroshi, N.;
Ryu, N. J. Med. Chem. 2001, 44, 4641–4649. (e) Piyasena, H.; Matthew,
E.; Sandra, L. M.; Jay, K.; Harvey, W.; Christopher, G. B.; Debra, J. P.;
Gao, Q.; Stella, H.; Valentin, K. G.; Nicholas, A. M. J. Med. Chem.
2002, 45, 1487–1499. (f) Teruhisa, T.; Hume, W. E.; Nagamine, J.;
Kawamura, T.; Mutsuo, T.; Nagata, R. Bioorg. Med. Chem. Lett. 2005,
15, 1789–1792. (g) Eugenia, M. L.; Raquel, P. H.; Mathias, C. Nat. Prod.
Rep. 2010, 27, 1138–1167.
(8) Zhou, F.; Liu, Y.-L.; Zhou, J. Adv. Synth. Catal. 2010, 352, 1381–
1407.
(9) (a) Ishimaru, T.; Shibata, N.; Nagai, J.; Nakamura, S.; Toru, T.;
Kanemasa, S. J. Am. Chem. Soc. 2006, 128, 16488–16489. (b) Sano, D.;
Nagata, K.; Itoh, T. Org. Lett. 2008, 10, 1593–1595. (c) Bui, T.; Candeias,
N. R.; Barbas, C. F., III J. Am. Chem. Soc. 2010, 132, 5574–5575.
(10) Ma, T.; Fu, X.; Kee, C.; Zong, L.; Pan, Y.; Huang, K.-W.; Tan,
C.-H. J. Am. Chem. Soc. 2011, 133, 2828–2831.
(11) See the Supporting Information for details.
Org. Lett., Vol. 14, No. 18, 2012
4763